Curanex Pharmaceuticals (CURX) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
There is no meaningful price-target consensus for Curanex Pharmaceuticals (CURX): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. No analyst publishes estimates on it either. What is left is the latest reported figures, the drivers and the risks below, which you assess yourself. Walnut is not an investment adviser.
Why CURX has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. CURX is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.
For a company like Curanex, traditional valuation metrics such as price-to-earnings or revenue multiples do not apply, because there is no revenue and the losses reflect the cost of preparing for trials. What matters is the cash runway versus the cost of clinical development, the credibility of the IND and trial timeline, and how much dilution future financings may cause. A market value near $7.5 million, about 1.4 times book value, with under $3 million of cash and a burn rate several times that, signals that the market is pricing in significant financing and execution risk rather than near-term clinical value.
CURX: the latest reported figures
No analyst publishes estimates on CURX, so these are the most recent figures we hold, as of October 2026. They describe where the company stands, not where it is going.
- Stage: Pre-clinical, pre-revenue
- Product revenue: $0 (no approved products)
- Net loss (TTM to Jun 2026): ~$10.5M (EPS ~-$7.80, split-adjusted)
- Cash / debt (Jun 30, 2026): ~$2.9M / ~$0.3M
- Operating cash flow (TTM): ~-$12M
- Market cap: ~$7.5M
- Shares outstanding (post 1-for-20 split): ~1.6M
Is there a 2030 forecast for CURX?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering CURX do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Curanex Pharmaceuticals can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move CURX from here
In short: the drivers cited most often are A single asset aimed at a large market, Long human-use history as the differentiator, Regulatory milestones are the catalysts. The risk cited most often against it is curanex is a pre-revenue, pre-clinical micro-cap with an unusually narrow base: a single drug candidate that has not yet entered human trials, an IND filing only targeted for late 2026, and years of clinical work and regulatory review ahead before any potential approval.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CURX is it a buy page.
Your questions about Curanex Pharmaceuticals
Ask Walnut's AI anything about CURX and see how it fits what you own.
FAQ
What is the price target for Curanex Pharmaceuticals (CURX)?
+
There is no meaningful consensus price target for CURX, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does CURX have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean the analysis starts with you, because there is no published model to build on.
What could move CURX?
+
The drivers and the risks are laid out on this page and in more depth on the CURX "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.